3,9-Bis(bromomethyl)-2,4,8,10-tetraoxaspiro<5.5>undecane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 3,9-Bis(bromomethyl)-2,4,8,10-tetraoxaspiro<5.5>undecane
• 英文别名: 3,9-dibromomethyl-2,4,8,10-tetraoxaspiro-[5.5]undecane；BBTU；3,9-bis-bromomethyl-2,4,8,10-tetraoxa-spiro[5.5]undecane；3,9-Bis-brommethyl-2,4,8,10-tetraoxa-spiro[5.5]undecan；3,9-Bisbromomethyl-2,4,8,10-tetraoxa-spiro[5,5]undecane；3,9-bis(bromomethyl)-2,4,8,10-tetraoxaspiro[5.5]undecane
• 化学式: C₉H₁₄Br₂O₄
• 分子量: 346.016
• InChiKey: BKNLRROAVXJIES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,9-Bis(bromomethyl)-2,4,8,10-tetraoxaspiro<5.5>undecane 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 反应 12.0h， 以83%的产率得到3,9-dimethylene-2,4,8,10-tetraoxaspiro-[5.5]undecane
  参考文献：
  名称：

  四价铂化合物-双环双键两亲性聚合物前药、 其纳米胶束及制备方法和应用

  摘要：

  本发明公开了一种四价铂化合物‑双环双键两亲性聚合物前药，其具有式(I)所示结构：其中，m＝1时，表示m＝0时，表示R表示‑CH3或‑CH2CH3，L1和L2相互独立地为Cl、N3、NO3、或n为10至80。还公开其制备方法，该方法包括使轴向双羟基配位的四价铂化合物与双环双键原酸酯前体进行反应的步骤。另外，还公开由其形成的纳米胶束及其应用。本发明的优点在于：本发明的两亲性聚合物前药和由其形成的胶束具有pH超敏和还原双重响应性，并且由其制备的抗肿瘤纳米药物新制剂具有良好的生物降解性能、优秀的肿瘤细胞毒性、相对长时间血液循环的稳定性以及一定的肿瘤靶向功能。

  公开号：

  CN108144067B
• 作为产物：
  描述：

  3,9-二甲基-2,4,8,10-四氧杂螺[5.5]十一烷 在 溴 作用下， 以 乙醚 为溶剂， 反应 1.0h， 以73%的产率得到3,9-Bis(bromomethyl)-2,4,8,10-tetraoxaspiro<5.5>undecane
  参考文献：
  名称：

  Zur Stereochemie einiger neuer chiraler Bromverbindungen mit einem 2,4,8,10-Tetraoxaspiro[5.5]-undecan ? Ger�st

  摘要：

  New compounds containing the 2,4,8,10-tetraoxaspiro[5.5] undecanic skeleton, substituted with brominated groups, have been synthesized by a regioselective radicalic bromination reaction. The stereochemistry of the compounds was studied by high resolution NMR methods. The anancomericity or the flipping of the rings was inferred from the conformational analysis. The chirality of the spiranic skeleton was investigated by means of the diastereotopicity of hydrogen and carbon atoms.

  DOI：

  10.1007/bf00811022

文献信息

• Tetravalent platinum compound-bicyclic double-bond-containing amphiphilic polymer prodrug, nano-micelle, preparation method and application thereof
  申请人：ANHUI UNIVERSITY

  公开号：US10947261B2

  公开（公告）日：2021-03-16

  A tetravalent platinum compound-bicyclic double-bond-containing amphiphilic polymer prodrug, which has the structure as shown in formula (I): when m=1, represents when m=0, represents R represents —CH3 or —CH2CH3; L1 and L2 independently represent Cl, N3, NO3, and n is from 10 to 80. A preparation method of the prodrug is also disclosed. The method includes a step of reacting an axially dihydroxy-coordinated tetravalent platinum compound with a bicyclic double-bond-containing orthoester precursor. In addition, a nano-micelle formed by the prodrug and an application thereof are further disclosed. The amphiphilic polymer prodrug and the micelle formed therefrom have pH hypersensitivity and reduction dual responsiveness.

  一种四价铂化合物-含双环双键两亲聚合物原药，其结构如式（I）所示： 当 m=1、 代表 当 m=0 时、 代表 R 代表-CH3 或-CH2 ；L1 和 L2 独立地代表 Cl、N3、NO3、 n 为 10 至 80。还公开了一种原药的制备方法。该方法包括将轴向二羟基配位的四价铂化合物与含双环双键的正酯前体反应的步骤。此外，还进一步公开了由原药形成的纳米胶束及其应用。两亲性聚合物原药及其形成的胶束具有 pH 超敏性和还原双重响应性。
• Tetravalent Platinum Compound-Bicyclic Double-bond-containing Amphiphilic Polymer Prodrug, Nano-micelle, Preparation Method and Application Thereof
  申请人：ANHUI UNIVERSITY

  公开号：US20190345181A1

  公开（公告）日：2019-11-14

  A tetravalent platinum compound-bicyclic double-bond-containing amphiphilic polymer prodrug, which has the structure as shown in formula (I): when m=1, represents when m=0, represents R represents —CH 3 or —CH 2 CH 3 ; L 1 and L 2 independently represent Cl, N 3 , NO 3 , and n is from 10 to 80. A preparation method of the prodrug is also disclosed. The method includes a step of reacting an axially dihydroxy-coordinated tetravalent platinum compound with a bicyclic double-bond-containing orthoester precursor. In addition, a nano-micelle formed by the prodrug and an application thereof are further disclosed. The amphiphilic polymer prodrug and the micelle formed therefrom have pH hypersensitivity and reduction dual responsiveness.